The recent treatment successes for progressive MS include sphingosine-1-phosphate (S1P) receptor modulator (siponimod), B-cell targeted therapy (ocrelizumab), and selective immune reconstitution therapy (cladribine) [256], while mitoxantrone and beta-interferon were the first few drugs used for treatment of SPMS. This evidence concerns the gene IFNB1 and secondary progressive multiple sclerosis.